F P Bymaster

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex
    Frank P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Psychopharmacology (Berl) 160:353-61. 2002
  2. ncbi New approaches to developing antidepressants by enhancing monoaminergic neurotransmission
    Frank P Bymaster
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Expert Opin Investig Drugs 12:531-43. 2003
  3. ncbi Receptor reserve of phosphoinositide-coupled muscarinic receptors in mouse hippocampus in vivo
    F P Bymaster
    Neuroscience Research Division, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Brain Res 916:165-71. 2001
  4. ncbi Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine
    F P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0501, USA
    Eur J Pharmacol 430:341-9. 2001
  5. ncbi Muscarinic mechanisms of antipsychotic atypicality
    Frank P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Prog Neuropsychopharmacol Biol Psychiatry 27:1125-43. 2003
  6. ncbi Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents
    F P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Indianapolis, IN 46285 0510, USA
    Mol Psychiatry 7:S57-63. 2002
  7. ncbi Muscarinic receptors as a target for drugs treating schizophrenia
    Frank P Bymaster
    Neuroscience Research Division, Eli Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Curr Drug Targets CNS Neurol Disord 1:163-81. 2002
  8. ncbi Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity
    Frank P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, USA
    Eur J Neurosci 17:1403-10. 2003
  9. ncbi Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system
    Frank P Bymaster
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Neurochem Res 28:437-42. 2003
  10. ncbi Investigations into the physiological role of muscarinic M2 and M4 muscarinic and M4 receptor subtypes using receptor knockout mice
    F P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Life Sci 68:2473-9. 2001

Collaborators

Detail Information

Publications51

  1. ncbi Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex
    Frank P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Psychopharmacology (Berl) 160:353-61. 2002
    ..The effect of other SSRIs on monoamine concentrations in prefrontal cortex has not been thoroughly studied...
  2. ncbi New approaches to developing antidepressants by enhancing monoaminergic neurotransmission
    Frank P Bymaster
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Expert Opin Investig Drugs 12:531-43. 2003
    ..The differing mechanisms of action possessed by these novel monoamine-enhancing compounds will offer greater treatment flexibility in the therapeutic management of MDD...
  3. ncbi Receptor reserve of phosphoinositide-coupled muscarinic receptors in mouse hippocampus in vivo
    F P Bymaster
    Neuroscience Research Division, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Brain Res 916:165-71. 2001
    ..Since pilocarpine is a relatively weak partial agonist, these data suggest a substantial level of receptor reserve for the PI response in mouse hippocampus...
  4. ncbi Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine
    F P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0501, USA
    Eur J Pharmacol 430:341-9. 2001
    ..Thus, olanzapine was not an agonist, but was a potent antagonist at 5-HT(6) receptors and had marked antagonism at 5-HT(3) receptors...
  5. ncbi Muscarinic mechanisms of antipsychotic atypicality
    Frank P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Prog Neuropsychopharmacol Biol Psychiatry 27:1125-43. 2003
    ..However, olanzapine significantly occupies central muscarinic receptors in humans. Overall, the role of muscarinic receptors in the antipsychotic effects of clozapine and olanzapine is controversial and complex...
  6. ncbi Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents
    F P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Indianapolis, IN 46285 0510, USA
    Mol Psychiatry 7:S57-63. 2002
    ..Olanzapine may normalize mood due to antidepressant-like activities, such as 5-HT(2A) receptor antagonism and increasing cortical norepinephrine and dopamine...
  7. ncbi Muscarinic receptors as a target for drugs treating schizophrenia
    Frank P Bymaster
    Neuroscience Research Division, Eli Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Curr Drug Targets CNS Neurol Disord 1:163-81. 2002
    ..Thus, we hypothesize that a combined M(1) agonist to promote cognition and a M(4) agonist for antipsychotic-like effects would treat the symptom domains of schizophrenia without parasympathomimetic side effects...
  8. ncbi Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity
    Frank P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, USA
    Eur J Neurosci 17:1403-10. 2003
    ..Muscarinic M1 receptors appear to be the only muscarinic receptor subtype mediating seizures...
  9. ncbi Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system
    Frank P Bymaster
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Neurochem Res 28:437-42. 2003
    ..M4 mAChRs modulate dopamine activity in motor tracts and act as inhibitory autoreceptors in striatum. Thus, as elucidated by gene targeting technology, mAChRs have widespread and manifold functions in the periphery and brain...
  10. ncbi Investigations into the physiological role of muscarinic M2 and M4 muscarinic and M4 receptor subtypes using receptor knockout mice
    F P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285 0510, USA
    Life Sci 68:2473-9. 2001
    ..The data demonstrate the usefulness of knockout mice in determining the physiological function of peripheral and central muscarinic receptors...
  11. ncbi Arachidonic acid release in cell lines transfected with muscarinic receptors: a simple functional assay to determine response of agonists
    F P Bymaster
    Lilly Neuroscience Research, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Cell Signal 11:405-13. 1999
    ..It is concluded that arachidonic acid release is a simple assay suitable for evaluation of muscarinic agonists, antagonists and the flux of external calcium into cells...
  12. ncbi Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects
    F P Bymaster
    Lilly Neuroscience Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Brain Res 795:179-90. 1998
    ....
  13. ncbi Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro
    F P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Schizophr Res 37:107-22. 1999
    ..Olanzapine was a weaker antagonist at muscarinic and dopamine D1 receptors...
  14. ncbi Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder
    Frank P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 27:699-711. 2002
    ..In contrast to methylphenidate, atomoxetine did not increase DA in striatum or nucleus accumbens, suggesting it would not have motoric or drug abuse liabilities...
  15. ncbi Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium
    F P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Eur J Pharmacol 390:245-8. 2000
    ..5 to 73 nM in intact cells. These data suggest that the affinity of olanzapine and clozapine for muscarinic receptors have been significantly overestimated...
  16. ncbi Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats
    H E Shannon
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Pharmacol Exp Ther 290:901-7. 1999
    ....
  17. ncbi Elucidating the role of muscarinic receptors in psychosis
    C C Felder
    Neuroscience Division, Eli Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Life Sci 68:2605-13. 2001
    ..These findings support a role for the development of M1 and M4 receptor agonists for diseases in which symptoms include cognitive impairment and psychotic behaviors...
  18. ncbi Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice
    E T Tzavara
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Mol Psychiatry 8:673-9. 2003
    ..Together these results suggest a crucial role for muscarinic M2 and M4 receptors in the tonic and phasic regulation of acetylcholine efflux in the hippocampus as well as in cognitive processes...
  19. ncbi Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity
    P Sauerberg
    Health Care Discovery, Novo Nordisk A S, Novo Nordisk Park, 2760 Malov, Denmark, and Neuroscience Research, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Med Chem 41:4378-84. 1998
    ..A model explaining the potency differences of closely related compounds is offered. The data suggest that muscarinic agonists act as functional dopamine antagonists and that they could become a novel treatment of psychotic patients...
  20. ncbi Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice
    H E Shannon
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Schizophr Res 42:249-59. 2000
    ....
  21. ncbi Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine
    E T Tzavara
    Eli Lilly and Company, Lilly Corporate Center, Neuroscience Discovery Research, Indianapolis, IN 46285, USA
    Mol Psychiatry 11:187-95. 2006
    ..We showed that, consistent with its cortical procholinergic and catecholamine-enhancing profile, atomoxetine (1-3 mg/kg, p.o.) significantly ameliorated performance in the object recognition test and the radial arm-maze test...
  22. ncbi Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors
    F P Bymaster
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Neuropsychopharmacology 25:871-80. 2001
    ..9 and 94 mg/kg for blocking p-chloramphetamine- and 6-hydroxydopamine-induced monoamine depletion, respectively. Thus, duloxetine more potently blocks 5-HT and NE transporters in vitro and in vivo than venlafaxine...
  23. ncbi Muscarinic agonist-mediated increases in serum corticosterone levels are abolished in m(2) muscarinic acetylcholine receptor knockout mice
    S K Hemrick-Luecke
    Neuroscience Division, Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Pharmacol Exp Ther 303:99-103. 2002
    ..These data suggest that the muscarinic M(2) receptor subtype mediates muscarinic agonist-induced activation of the hypothalamic-pituitary-adrenocortical axis in mice...
  24. ncbi The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells
    K Eckols
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Life Sci 57:1183-90. 1995
    ..These results demonstrate that xanomeline increased APPs release by activation of m1 muscarinic receptors and support the possibility that cholinergic replacement therapy for Alzheimer's Disease may reduce amyloid deposition...
  25. ncbi The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex
    K W Perry
    Eli Lilly and Company Research Laboratories, Neuroscience Research Division, Lilly Corporate Center, Indianapolis, IN 46285-0510, USA
    Biol Psychiatry 49:716-25. 2001
    ..Based on the antipsychotic-like activity of xanomeline in Alzheimer's patients and the similarity to atypical antipsychotic agents, we suggest that xanomeline may be a novel antipsychotic agent...
  26. ncbi The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus
    E T Tzavara
    Eli Lilly and Company, Lilly Corporate Center, Neuroscience Discovery Research, Indianapolis, IN 46285-0510, USA
    Eur J Pharmacol 426:R3-4. 2001
    ..This increase in norepinephrine outflow could play an important role in the pharmacological and potentially therapeutic actions of SR141716A...
  27. ncbi A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data
    J S Kennedy
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Int J Geriatr Psychiatry 16:S33-61. 2001
    ....
  28. ncbi Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial
    J S Kennedy
    Indiana University School of Medicine, Department of Psychiatry, Indianapolis, Indiana, USA
    Int J Geriatr Psychiatry 18:1013-20. 2003
    ..To compare the six-week clinical response and safety profile of schizophrenia patients, age > or =60 years, receiving olanzapine (OLZ) vs haloperidol (HAL) in a double blind, randomized trial...
  29. ncbi Metabotropic glutamate receptor activation produces extrapyramidal motor system activation that is mediated by striatal dopamine
    A I Sacaan
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285
    J Neurochem 59:245-51. 1992
    ..These results suggest a functional interaction between the metabotropic EAA receptor and the dopaminergic system in the striatum...
  30. ncbi Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake
    F P Bymaster
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 13:4477-80. 2003
    ..One member of this series, duloxetine (Cymbalta) has proven to be effective in clinical trials for the treatment of depression...
  31. pmc Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease
    Y Du
    Departmens of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Proc Natl Acad Sci U S A 98:14669-74. 2001
    ..Thus, NO appears to play an important role in MPTP neurotoxicity. Neuroprotective tetracyclines may be effective in preventing or slowing the progression of Parkinson's and other neurodegenerative diseases...
  32. ncbi Current perspectives on the development of non-biogenic amine-based antidepressants
    P Skolnick
    Neuroscience Discovery, Eli Lilly and Co, Lilly Corporate Center, DC 0510, Indianapolis, IN 46285 0510, USA
    Pharmacol Res 43:411-23. 2001
    ..Drugs emerging from these strategies may offer significant advantages over currently used antidepressants...
  33. pmc The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions
    Eleni T Tzavara
    Eli Lilly and Company, Lilly Corporate Center, DC0510, Neuroscience Discovery Research, Indianapolis, IN 46285 0510, USA
    Br J Pharmacol 138:544-53. 2003
    ....
  34. ncbi M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies
    Eleni T Tzavara
    Eli Lilly and Co, Indianapolis, Indiana 46240 0510, USA
    FASEB J 18:1410-2. 2004
    ..We propose that M4 receptor agonists could represent an innovative strategy for the treatment of pathologies associated with hyperdopaminergia...
  35. ncbi Amantadine for weight gain associated with olanzapine treatment
    Walter Deberdt
    Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Drop Code 4133, Indianapolis, IN 46285, USA
    Eur Neuropsychopharmacol 15:13-21. 2005
    ..Overall, amantadine was safe, was well tolerated, and attenuated weight gain or promoted weight loss in some patients who had gained weight during olanzapine therapy...
  36. ncbi The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression
    Frank P Bymaster
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Curr Pharm Des 11:1475-93. 2005
    ..More importantly, duloxetine appears to have better response rates and remission from depressive symptoms, perhaps due to its ability to treat a wider range of symptoms...
  37. ncbi Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine
    Kurt Rasmussen
    Lilly Research Laboratories, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 315:1265-77. 2005
    ..FMPD has the potential to have efficacy in treating schizophrenia and bipolar mania with a low risk of treatment-emergent extrapyramidal symptoms, prolactin elevation, and weight gain. Clinical trials are needed to test these hypotheses...
  38. ncbi Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat
    Chad J Swanson
    Lundbeck Research USA, 215 College Road, Paramus, NJ 07652 1431, USA
    Neuropharmacology 50:755-60. 2006
    ....
  39. pmc Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody
    Kelly R Bales
    Neuroscience Discovery Research, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Invest 116:825-32. 2006
    ..Treatment with certain anti-A beta antibodies may therefore rapidly reverse this cholinergic dysfunction and relieve memory deficits associated with early AD...
  40. ncbi Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles
    Simi Vincent
    Autonomic Dysfunction Center, Departments of Medicine, Pharmacology, and Neurology, Vanderbilt University, Nashville, Tenn 37232 2195, USA
    Circulation 109:3202-7. 2004
    ....
  41. ncbi Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat
    Susanne Koch
    Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Neuropharmacology 46:232-42. 2004
    ..The wide-ranging neurochemical effects of this drug combination may make it particularly useful as a treatment for complex, resistant depressions...
  42. ncbi Dual monoamine modulation for improved treatment of major depressive disorder
    Pierre V Tran
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 23:78-86. 2003
    ..Potential neurobiological substrates mediating the enhanced antidepressant activity of dual reuptake inhibitors are discussed...
  43. ncbi R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study
    Susanne Koch
    Lilly Research Laboratories, Neuroscience Discovery Research, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuropsychopharmacology 27:949-59. 2002
    ..The unexpected increases of extracellular catecholamines by a selective 5-HT uptake inhibitor like R-fluoxetine may be due to its antagonism of 5-HT(2C) receptors...
  44. ncbi M1 muscarinic receptor signaling in mouse hippocampus and cortex
    Amy C Porter
    Lilly Research Laboratories, Neuroscience Research Division, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 0510, USA
    Brain Res 944:82-9. 2002
    ..These findings support a role for the M1 receptor subtype as the primary G(alpha)(q)/11-coupled muscarinic receptor in mouse hippocampus and cortex...
  45. ncbi Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study
    Stephan A Chalon
    Lilly Research Laboratories, Mont Saint Guibert, Belgium
    Neuropsychopharmacology 28:1685-93. 2003
    ..The lack of a detectable impact of duloxetine on TYR PD30 suggests that this may not be the most sensitive indirect measure of NE reuptake when assessing dual reuptake inhibitors...
  46. doi Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia
    Anantha Shekhar
    Department of Psychiatry, Indiana University School of Medicine, 1111 West 10th St, Suite 313, Indianapolis, IN 46202, USA
    Am J Psychiatry 165:1033-9. 2008
    ..The authors studied xanomeline, a relatively selective muscarinic type 1 and type 4 (M(1) and M(4)) receptor agonist, to determine if this agent is effective in the treatment of schizophrenia...
  47. ncbi Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?
    David T Wong
    Department of Psychiatry, Indiana University Medical School, Indianapolis 46202, USA
    Prog Drug Res 58:169-222. 2002
    ....
  48. ncbi Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats
    Susanne Koch
    Lilly Neuroscience Research Division, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Neuropharmacology 45:935-44. 2003
    ..Chlorimipramine, duloxetine, and high dose venlafaxine acted as dual transporter inhibitors in rat PFC and increased extracellular concentrations of the monoamines, indicating functional dual transporter inhibition...
  49. ncbi Treatment of glossodynia with olanzapine
    Carrie L Gick
    Department of Dermatology, Indiana University School of Medicine, Indiana University School of Dentistry, Indianapolis, IN 46202, USA
    J Am Acad Dermatol 51:463-5. 2004
    ..Improvement of pain symptoms were noted within 3 days with full resolution of symptoms at 1- and 3-month follow-ups. Dysphoria and anticipatory anxiety remitted fully upon pain relief...
  50. ncbi Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor
    Amy C Porter
    Lilly Research Laboratories, Neuroscience Division, Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN, USA
    J Pharmacol Exp Ther 301:1020-4. 2002
    ..As a potential endogenous antagonist at the CB1 receptor, virodhamine adds a new form of regulation to the endocannabinoid system...
  51. ncbi Case history: the discovery of fluoxetine hydrochloride (Prozac)
    David T Wong
    Department of Psychiatry, Indiana University School of Medicine, Indianapolis 46202, USA
    Nat Rev Drug Discov 4:764-74. 2005
    ..Here, we summarize this research and discuss the many challenges that we encountered during the development of fluoxetine hydrochloride, which has now been widely acknowledged as a breakthrough drug for depression...